1. A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA. (12th June 2019) Authors: Lynch, R.C.; Smith, S.D.; Shadman, M.; Ujjani, C.S.; Kurtz, D.M.; Coye, H.; Till, B.G.; Warren, E.H.; Shustov, A.R.; Maloney, D.G.; Tseng, Y.D.; Gopal, A.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 572 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A WINDOW STUDY OF IXAZOMIB IN UNTREATED B‐NHL. (12th June 2019) Authors: Graf, S.A.; Lynch, R.C.; Ujjani, C.; Coffey, D.G.; Smith, S.D.; Shadman, M.; Warren, E.H.; Libby, E.N.; Godwin, C.; Cassaday, R.D.; Gooley, T.; Fromm, J.R.; Gopal, A.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 570 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. (June 2017) Authors: Fowler, N.; Gopal, A.K.; Schuster, S.J.; Trotman, J.; Hess, G.; Hou, J.; Yacoub, A.; Lill, M.; Martin, P.; Vitolo, U.; Spencer, A.; Radford, J.; Jurczak, W.; Morton, J.; Osmanov, D.; Caballero, D.; Deshpande, S.; Vermeulen, J.; Damle, R.; Schaffer, M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 210 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PEMBROLIZUMAB WITH RCHOP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL AND GRADE 3B FOLLICULAR LYMPHOMA: FINAL RESULTS OF A PHASE I TRIAL. (12th June 2019) Authors: Smith, S.D.; Lynch, R.C.; Till, B.G.; Cowan, A.J.; Wu, Q.V.; Voutsinas, J.M.; Shadman, M.; Shustov, A.; Cassaday, R.D.; Fromm, J.R.; Gopal, A.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 120 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULTS AFTER CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR‐MODIFIED T‐CELL (CAR‐T) THERAPY. (12th June 2019) Authors: Shadman, M.; Gauthier, J.; Hay, K.A.; Voutsinas, J.M.; Milano, F.; Li, A.; Hirayama, A.V.; Sorror, M.L.; Cassaday, R.D.; Till, B.G.; Gopal, A.K.; Sandmaier, B.M.; Maloney, D.G.; Turtle, C.J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. TREATMENT EMERGENT ADVERSE EVENTS VARY WITH DIFFERENT PI3K INHIBITORS. (12th June 2019) Authors: Awan, F.T.; Chan, R.J.; Gu, L.; Xing, G.; Bhargava, P.; Ruzicka, B.; Dreyling, M.; Zinzani, P.; Gopal, A.K. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 523 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗